Anti-Phospho-Tau Gene Therapy for Chronic Traumatic Encephalopathy.

Publication Type	Academic Article
Authors	Sacramento C, Sondhi D, Rosenberg J, Chen A, Giordano S, Pey E, Lee V, Stiles K, Havlicek D, Leopold P, Kaminsky S, Crystal R
Journal	Hum Gene Ther
Volume	31
Issue	1-2
Pagination	57-69
Date Published	12/13/2019
ISSN	1557-7422
Keywords	Chronic Traumatic Encephalopathy, Genetic Therapy, tau Proteins
Abstract	Chronic traumatic encephalopathy (CTE) is a progressive neurodegenerative disorder caused by repetitive trauma to the central nervous system (CNS) suffered by soldiers, contact sport athletes, and civilians following accident-related trauma. CTE is a CNS tauopathy, with trauma-induced inflammation leading to accumulation of hyperphosphorylated forms of the microtubule-binding protein Tau (pTau), resulting in neurofibrillary tangles and progressive loss of neurons. At present, there are no therapies to treat CTE. We hypothesized that direct CNS administration of an adeno-associated virus (AAV) vector coding for an anti-pTau antibody would generate sufficient levels of anti-pTau in the CNS to suppress pTau accumulation thus interrupting the pathogenic process. Using a serotype AAVrh.10 gene transfer vector coding for a monoclonal antibody directed against pTau, we demonstrate the feasibility of this strategy in a murine CTE model in which pTau accumulation was elicited by repeated traumatic brain injury (TBI) using a closed cortical impact procedure over 5 days. Direct delivery of AAVrh.10 expression vectors coding for either of the two different anti-pTau antibodies to the hippocampus of these TBI mice significantly reduced pTau levels across the CNS. Using doses that can be safely scaled to humans, the data demonstrate that CNS administration of AAVrh.10anti-pTau is effective, providing a new strategy to interrupt the CTE consequences of TBI.
DOI	10.1089/hum.2019.174
PubMed ID	31608704